Ridaforolimus

Type: Product
Name: Ridaforolimus
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Researchers' Work from Children's Hospital Focuses on Adverse Drug Reactions (A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and...

Researchers' Work from Children's Hospital Focuses on Adverse Drug Reactions (A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumors)By a News Reporter-Staff News ... [Published Pharmacy Choice - Aug 06 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

The PI3K/AKT/ mTOR Pathway in Breast Cancer

Andre, F., Campone, M., O'Regan, R., Manlius, C., Massacesi, C., Sahmoud, T. et al. (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28: 5110 ... [Published General Medicine eJournal - Jul 28 2014]
First reported May 13 2014 - Updated May 13 2014 - 1 reports

IMPAKT Combination of mTOR and AKT inhibitors in patients with advanced breast cancer

A combination of mTOR inhibitor, ridaforolimus and novel AKT inhibitor, MK-2206, showed activity in heavily pretreated hormone positive and negative breast cancer patients who exhibit PI3K pathway dependence, based on low RAS signature score. The...Related ... [Published BioPortfolio - May 13 2014]

Quotes

According to the news editors, the research concluded: "Ridaforolimus may represent a therapeutic option for use in pediatric malignancies."
NEXT ARTICLE More From BioPortfolio on "IMPAKT: Combination of mTOR and AKT inhibitors in patients with advanced breast cancer"

More Content

All (5) | News (3) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Researchers' Work from Children's Hospital Focu... [Published Pharmacy Choice - Aug 06 2014]
The PI3K/AKT/ mTOR Pathway in Breast Cancer [Published General Medicine eJournal - Jul 28 2014]
IMPAKT Combination of mTOR and AKT inhibitors i... [Published BioPortfolio - May 13 2014]
DOTW Keeps Tabs As Tax Trimming Fuels Deals [Published The IN VIVO Blog - Feb 28 2014]
Merck Abandons Once-Promising Experimental Canc... [Published Wall St. Cheat Sheet - Feb 25 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
DOTW Keeps Tabs As Tax Trimming Fuels Deals [Published The IN VIVO Blog - Feb 28 2014]
As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in other sectors. But that doesn’t mean they have stopped ...
Merck Abandons Once-Promising Experimental Canc... [Published Wall St. Cheat Sheet - Feb 25 2014]
Merck & Co. Inc.  ( NYSE:MRK ) has officially washed its hands of a once-lauded experimental cancer drug it invested in along with Ariad Pharmaceuticals Inc.  ( NASDAQ:ARIA ) Merck informed Ariad last week that it was terminating its license agreement ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.